STERIS PLC, a global infection prevention and procedural products company, has seen its shares more than double in value over the past two years, driven by strong operational performance, strategic innovation, and a favorable reimbursement climate, …

Alcon AG’s share price declined amid market volatility, raising concerns about the company’s valuation and the pending acquisition of STAAR Surgical, but its long-term prospects remain strong due to its position in the growing ophthalmic device mark…

Revvity Inc. has partnered with Profluent to develop and commercialize AI-enhanced adenine deaminase-based Pin-point base editing systems, aiming to deliver precise and high-throughput genome editing capabilities for researchers and clinicians.

Demant A/S, a leading Danish provider of hearing solutions, has seen its share price decline modestly due to broader market weakness, but its strong fundamentals and innovation pipeline are expected to underpin medium-term resilience.

Smith & Nephew PLC, a leading medical-device company, has seen its share price increase by 17% over the past year, driven by its robust product portfolio, continuous innovation, and disciplined operational execution, outpacing the broader FTSE 100 b…

Haleon PLC’s share price has remained relatively stable despite market volatility, thanks to strategic share repurchases and a growing global presence through its partnership with Wellnex Life.

Quest Diagnostics Inc. is advancing its role in cancer research through strategic partnerships and clinical collaborations, driving innovation and attracting investor interest in the process.

Argenx SE, a European biopharmaceutical firm, has experienced a short-term decline in its share price, but its inclusion in the Euro Stoxx 50 index and strong positioning in the autoimmune and oncology markets reinforce its long-term value propositi…

IDEXX Laboratories Inc. has experienced significant capital appreciation over the past three years, driven by its robust performance in veterinary diagnostics, food safety testing, and water quality assessment, and is well-positioned to sustain its …

Pfizer Inc. has announced its acquisition of Metsera, a biotechnology company focused on anti-obesity therapies, in a deal valued at $47.50 per share with potential upside to $70 per share, marking Pfizer’s first significant transaction in two years…